Eli Lilly Canada Inc.

13 articles with Eli Lilly Canada Inc.

• Health Canada has approved TALTZ® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)

  2/11/2020

  Eli Lilly Canada announced that Health Canada approved TALTZ® on February 4, 2020, for the treatment of adult patients with active ankylosing spondylitis, which is also known as radiographic axial spondyloarthritis, who have responded inadequately to, or are intolerant to, conventional therapy.

• EMGALITY™ (galcanezumab) now available in Canada for preventive treatment of migraine

  10/2/2019

  New anti-CGRP treatment for the prevention of migraine in adults with at least 4 migraine days per month

• VERZENIO (abemaciclib) Available in Canada for Metastatic Breast Cancer

  8/8/2019

  Eli Lilly Canada Inc. (Lilly Canada) is pleased to announce the availability of VERZENIO™ (abemaciclib). VERZENIO is indicated for the treatment of estrogen and/or progesterone hormone receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-) metastatic breast cancer (

• With availability of Olumiant (baricitinib), Lilly brings new oral treatment option for Canadians living with rheumatoid arthritis

  11/1/2018

  "You would never know by looking at me," says Angela Vance, a Lilly employee, "that I have rheumatoid arthritis (RA)."

• Eli Lilly Canada and Women in Biz Network Partner to Shift Perceptions of Rheumatoid Arthritis in the Workplace

  10/12/2018

  A series of local events and career progression resources to support women living and working with a chronic disease

• Health Canada Approves Taltz (ixekizumab) for Treatment of Active Psoriatic Arthritis

  6/20/2018

  The approval of Taltz is based on the Phase 3 clinical trials that demonstrated efficacy on both joints and skin symptomsi

• Convenient prefilled insulin pen with flexible half-unit dosing approved and available in Canada

  5/3/2018

  Eli Lilly Canada Inc. (Lilly) is proud to announce that Humalog® [insulin lispro injection 100 units/mL] Junior KwikPen® is approved by Health Canada and now available to Canadians with diabetes.

• Eli Lilly Canada Inc. Release: Health Canada's Approval Of Taltz (Ixekizumab) Brings Targeted Therapy To Canadians Living With Moderate-To-Severe Plaque Psoriasis

  6/21/2016

• Boehringer Ingelheim And Eli Lilly Canada Inc. Release: Health Canada Approves JARDIANCE (empagliflozin) Tablets For Adults With Type 2 Diabetes

  11/30/2015

• Health Canada Approves Eli Lilly Canada Inc.'s Cymbalta for Knee Pain

  11/8/2012

• Boehringer Ingelheim Corporation and Eli Lilly Canada Inc. Present New linagliptin Data at American Diabetes Association's 72nd Scientific Sessions®

  6/11/2012

• FDA Delays Approval of Amylin Pharmaceuticals, Inc., Eli Lilly Canada Inc. (JOBS) Diabetes Drug; FDA Requests Finalization of Product Labeling

  3/15/2010

• Eli Lilly Turns To Japan

  3/25/2005